Improving the Treatment of Chronic Spontaneous Urticaria: What Does the Future Hold?

Program Overview

In this activity, a panel of experts discuss the current guideline-recommended treatment approach to chronic spontaneous urticaria (CSU), with a focus on treatment of patients with refractory disease requiring third-line therapy. The panel will also discuss advances in understanding the pathogenesis of disease, the role of type 2 inflammation, and emerging therapies.

Credit Expired

0.50 CE Credit(s)

Expires: December 8, 2022

Target Audience

This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
Assess current safety and efficacy data on emerging therapies for the treatment of CSU

Activity Faculty

Jonathan A. Bernstein, MD

Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Autumn Burnette, MD, FACAAI

Assistant Professor, Division of Allergy and Immunology
Howard University Hospital
Washington, DC

David M. Lang, MD

Professor and Chair, Medicine
Department of Allergy and Clinical Immunology
Respiratory Institute
Cleveland, OH

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Featured RMEI CE Activities

Closing the Gap: Personalized Approaches to Cervical Cancer Screening and Treatment

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care

Privacy | Terms of Use